Gravid Treatment

Gravid Treatment Comprehensive Study by Type (Topical Products, Lasers, Microdermabrasion, Others), Application (Hospitals, Clinics, Specialty Dermatology Centres, Home-use, Others) Players and Region - Global Market Outlook to 2026

Gravid Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Gravid Treatment Market?

Gravid treatment is known as pregnancy treatment. Increasing clinics in developing countries as well as rising technological advancement is driving the gravid treatment market. While some of the factors like lack of medical infrastructure in underdeveloped countries is restraining the market growth of gravid treatment.

The market study is being classified by Type (Topical Products, Lasers, Microdermabrasion and Others), by Application (Hospitals, Clinics, Specialty Dermatology Centres, Home-use and Others) and major geographies with country level break-up.

Laboratoires Expanscience (France), Clarins Group (France), Merz North AmericaInc. (Merz Group) (Germany), E.T. Browne Drug (United States), Syneron Medical Ltd. (United States), Union-Swiss (Pty) Ltd. (South Africa), Basq Skincare (United States), Ellipse A/S (Denmark), The Boppy Company (United States) and Helix BioMedix (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Weleda AG, Dermaclara, Mama Mio US and Centre Light Solutions.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Gravid Treatment market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Gravid Treatment market by Type, Application and Region.

On the basis of geography, the market of Gravid Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rising Number of Gravid Treatment Clinics in Developing Countries
  • Technological Advancements in Gravid Treatment Devices

Market Trend
  • Technological Improvements in Gravid Treatment in Hospitals

Restraints
  • Stringent Government Regulations
  • Lack of Medical Infrastructure in Underdeveloped Countries

Opportunities
  • Increased Government Spending On Medical Sector in Emerging Markets
  • Increase in Awareness about Gravid Treatment

Challenges
  • High Cost of Procedures





Key Target Audience
Gravid Treatment Device Manufacturers, Medical Device Suppliers and Distributors, Healthcare Service Providers and Research Laboratories

Report Objectives / Segmentation Covered

By Type
  • Topical Products
  • Lasers
  • Microdermabrasion
  • Others
By Application
  • Hospitals
  • Clinics
  • Specialty Dermatology Centres
  • Home-use
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of Gravid Treatment Clinics in Developing Countries
      • 3.2.2. Technological Advancements in Gravid Treatment Devices
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Procedures
    • 3.4. Market Trends
      • 3.4.1. Technological Improvements in Gravid Treatment in Hospitals
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gravid Treatment, by Type, Application and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Gravid Treatment (Value)
      • 5.2.1. Global Gravid Treatment by: Type (Value)
        • 5.2.1.1. Topical Products
        • 5.2.1.2. Lasers
        • 5.2.1.3. Microdermabrasion
        • 5.2.1.4. Others
      • 5.2.2. Global Gravid Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Specialty Dermatology Centres
        • 5.2.2.4. Home-use
        • 5.2.2.5. Others
      • 5.2.3. Global Gravid Treatment Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Gravid Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Laboratoires Expanscience (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Clarins Group (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merz North AmericaInc. (Merz Group) (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. E.T. Browne Drug (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Syneron Medical Ltd. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Union-Swiss (Pty) Ltd. (South Africa)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Basq Skincare (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Ellipse A/S (Denmark)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. The Boppy Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Helix BioMedix (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Gravid Treatment Sale, by Type, Application and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Gravid Treatment (Value)
      • 7.2.1. Global Gravid Treatment by: Type (Value)
        • 7.2.1.1. Topical Products
        • 7.2.1.2. Lasers
        • 7.2.1.3. Microdermabrasion
        • 7.2.1.4. Others
      • 7.2.2. Global Gravid Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Specialty Dermatology Centres
        • 7.2.2.4. Home-use
        • 7.2.2.5. Others
      • 7.2.3. Global Gravid Treatment Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gravid Treatment: by Type(USD Million)
  • Table 2. Gravid Treatment Topical Products , by Region USD Million (2015-2020)
  • Table 3. Gravid Treatment Lasers , by Region USD Million (2015-2020)
  • Table 4. Gravid Treatment Microdermabrasion , by Region USD Million (2015-2020)
  • Table 5. Gravid Treatment Others , by Region USD Million (2015-2020)
  • Table 6. Gravid Treatment: by Application(USD Million)
  • Table 7. Gravid Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 8. Gravid Treatment Clinics , by Region USD Million (2015-2020)
  • Table 9. Gravid Treatment Specialty Dermatology Centres , by Region USD Million (2015-2020)
  • Table 10. Gravid Treatment Home-use , by Region USD Million (2015-2020)
  • Table 11. Gravid Treatment Others , by Region USD Million (2015-2020)
  • Table 12. South America Gravid Treatment, by Country USD Million (2015-2020)
  • Table 13. South America Gravid Treatment, by Type USD Million (2015-2020)
  • Table 14. South America Gravid Treatment, by Application USD Million (2015-2020)
  • Table 15. Brazil Gravid Treatment, by Type USD Million (2015-2020)
  • Table 16. Brazil Gravid Treatment, by Application USD Million (2015-2020)
  • Table 17. Argentina Gravid Treatment, by Type USD Million (2015-2020)
  • Table 18. Argentina Gravid Treatment, by Application USD Million (2015-2020)
  • Table 19. Rest of South America Gravid Treatment, by Type USD Million (2015-2020)
  • Table 20. Rest of South America Gravid Treatment, by Application USD Million (2015-2020)
  • Table 21. Asia Pacific Gravid Treatment, by Country USD Million (2015-2020)
  • Table 22. Asia Pacific Gravid Treatment, by Type USD Million (2015-2020)
  • Table 23. Asia Pacific Gravid Treatment, by Application USD Million (2015-2020)
  • Table 24. China Gravid Treatment, by Type USD Million (2015-2020)
  • Table 25. China Gravid Treatment, by Application USD Million (2015-2020)
  • Table 26. Japan Gravid Treatment, by Type USD Million (2015-2020)
  • Table 27. Japan Gravid Treatment, by Application USD Million (2015-2020)
  • Table 28. India Gravid Treatment, by Type USD Million (2015-2020)
  • Table 29. India Gravid Treatment, by Application USD Million (2015-2020)
  • Table 30. South Korea Gravid Treatment, by Type USD Million (2015-2020)
  • Table 31. South Korea Gravid Treatment, by Application USD Million (2015-2020)
  • Table 32. Taiwan Gravid Treatment, by Type USD Million (2015-2020)
  • Table 33. Taiwan Gravid Treatment, by Application USD Million (2015-2020)
  • Table 34. Australia Gravid Treatment, by Type USD Million (2015-2020)
  • Table 35. Australia Gravid Treatment, by Application USD Million (2015-2020)
  • Table 36. Rest of Asia-Pacific Gravid Treatment, by Type USD Million (2015-2020)
  • Table 37. Rest of Asia-Pacific Gravid Treatment, by Application USD Million (2015-2020)
  • Table 38. Europe Gravid Treatment, by Country USD Million (2015-2020)
  • Table 39. Europe Gravid Treatment, by Type USD Million (2015-2020)
  • Table 40. Europe Gravid Treatment, by Application USD Million (2015-2020)
  • Table 41. Germany Gravid Treatment, by Type USD Million (2015-2020)
  • Table 42. Germany Gravid Treatment, by Application USD Million (2015-2020)
  • Table 43. France Gravid Treatment, by Type USD Million (2015-2020)
  • Table 44. France Gravid Treatment, by Application USD Million (2015-2020)
  • Table 45. Italy Gravid Treatment, by Type USD Million (2015-2020)
  • Table 46. Italy Gravid Treatment, by Application USD Million (2015-2020)
  • Table 47. United Kingdom Gravid Treatment, by Type USD Million (2015-2020)
  • Table 48. United Kingdom Gravid Treatment, by Application USD Million (2015-2020)
  • Table 49. Netherlands Gravid Treatment, by Type USD Million (2015-2020)
  • Table 50. Netherlands Gravid Treatment, by Application USD Million (2015-2020)
  • Table 51. Rest of Europe Gravid Treatment, by Type USD Million (2015-2020)
  • Table 52. Rest of Europe Gravid Treatment, by Application USD Million (2015-2020)
  • Table 53. MEA Gravid Treatment, by Country USD Million (2015-2020)
  • Table 54. MEA Gravid Treatment, by Type USD Million (2015-2020)
  • Table 55. MEA Gravid Treatment, by Application USD Million (2015-2020)
  • Table 56. Middle East Gravid Treatment, by Type USD Million (2015-2020)
  • Table 57. Middle East Gravid Treatment, by Application USD Million (2015-2020)
  • Table 58. Africa Gravid Treatment, by Type USD Million (2015-2020)
  • Table 59. Africa Gravid Treatment, by Application USD Million (2015-2020)
  • Table 60. North America Gravid Treatment, by Country USD Million (2015-2020)
  • Table 61. North America Gravid Treatment, by Type USD Million (2015-2020)
  • Table 62. North America Gravid Treatment, by Application USD Million (2015-2020)
  • Table 63. United States Gravid Treatment, by Type USD Million (2015-2020)
  • Table 64. United States Gravid Treatment, by Application USD Million (2015-2020)
  • Table 65. Canada Gravid Treatment, by Type USD Million (2015-2020)
  • Table 66. Canada Gravid Treatment, by Application USD Million (2015-2020)
  • Table 67. Mexico Gravid Treatment, by Type USD Million (2015-2020)
  • Table 68. Mexico Gravid Treatment, by Application USD Million (2015-2020)
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Gravid Treatment: by Type(USD Million)
  • Table 80. Gravid Treatment Topical Products , by Region USD Million (2021-2026)
  • Table 81. Gravid Treatment Lasers , by Region USD Million (2021-2026)
  • Table 82. Gravid Treatment Microdermabrasion , by Region USD Million (2021-2026)
  • Table 83. Gravid Treatment Others , by Region USD Million (2021-2026)
  • Table 84. Gravid Treatment: by Application(USD Million)
  • Table 85. Gravid Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 86. Gravid Treatment Clinics , by Region USD Million (2021-2026)
  • Table 87. Gravid Treatment Specialty Dermatology Centres , by Region USD Million (2021-2026)
  • Table 88. Gravid Treatment Home-use , by Region USD Million (2021-2026)
  • Table 89. Gravid Treatment Others , by Region USD Million (2021-2026)
  • Table 90. South America Gravid Treatment, by Country USD Million (2021-2026)
  • Table 91. South America Gravid Treatment, by Type USD Million (2021-2026)
  • Table 92. South America Gravid Treatment, by Application USD Million (2021-2026)
  • Table 93. Brazil Gravid Treatment, by Type USD Million (2021-2026)
  • Table 94. Brazil Gravid Treatment, by Application USD Million (2021-2026)
  • Table 95. Argentina Gravid Treatment, by Type USD Million (2021-2026)
  • Table 96. Argentina Gravid Treatment, by Application USD Million (2021-2026)
  • Table 97. Rest of South America Gravid Treatment, by Type USD Million (2021-2026)
  • Table 98. Rest of South America Gravid Treatment, by Application USD Million (2021-2026)
  • Table 99. Asia Pacific Gravid Treatment, by Country USD Million (2021-2026)
  • Table 100. Asia Pacific Gravid Treatment, by Type USD Million (2021-2026)
  • Table 101. Asia Pacific Gravid Treatment, by Application USD Million (2021-2026)
  • Table 102. China Gravid Treatment, by Type USD Million (2021-2026)
  • Table 103. China Gravid Treatment, by Application USD Million (2021-2026)
  • Table 104. Japan Gravid Treatment, by Type USD Million (2021-2026)
  • Table 105. Japan Gravid Treatment, by Application USD Million (2021-2026)
  • Table 106. India Gravid Treatment, by Type USD Million (2021-2026)
  • Table 107. India Gravid Treatment, by Application USD Million (2021-2026)
  • Table 108. South Korea Gravid Treatment, by Type USD Million (2021-2026)
  • Table 109. South Korea Gravid Treatment, by Application USD Million (2021-2026)
  • Table 110. Taiwan Gravid Treatment, by Type USD Million (2021-2026)
  • Table 111. Taiwan Gravid Treatment, by Application USD Million (2021-2026)
  • Table 112. Australia Gravid Treatment, by Type USD Million (2021-2026)
  • Table 113. Australia Gravid Treatment, by Application USD Million (2021-2026)
  • Table 114. Rest of Asia-Pacific Gravid Treatment, by Type USD Million (2021-2026)
  • Table 115. Rest of Asia-Pacific Gravid Treatment, by Application USD Million (2021-2026)
  • Table 116. Europe Gravid Treatment, by Country USD Million (2021-2026)
  • Table 117. Europe Gravid Treatment, by Type USD Million (2021-2026)
  • Table 118. Europe Gravid Treatment, by Application USD Million (2021-2026)
  • Table 119. Germany Gravid Treatment, by Type USD Million (2021-2026)
  • Table 120. Germany Gravid Treatment, by Application USD Million (2021-2026)
  • Table 121. France Gravid Treatment, by Type USD Million (2021-2026)
  • Table 122. France Gravid Treatment, by Application USD Million (2021-2026)
  • Table 123. Italy Gravid Treatment, by Type USD Million (2021-2026)
  • Table 124. Italy Gravid Treatment, by Application USD Million (2021-2026)
  • Table 125. United Kingdom Gravid Treatment, by Type USD Million (2021-2026)
  • Table 126. United Kingdom Gravid Treatment, by Application USD Million (2021-2026)
  • Table 127. Netherlands Gravid Treatment, by Type USD Million (2021-2026)
  • Table 128. Netherlands Gravid Treatment, by Application USD Million (2021-2026)
  • Table 129. Rest of Europe Gravid Treatment, by Type USD Million (2021-2026)
  • Table 130. Rest of Europe Gravid Treatment, by Application USD Million (2021-2026)
  • Table 131. MEA Gravid Treatment, by Country USD Million (2021-2026)
  • Table 132. MEA Gravid Treatment, by Type USD Million (2021-2026)
  • Table 133. MEA Gravid Treatment, by Application USD Million (2021-2026)
  • Table 134. Middle East Gravid Treatment, by Type USD Million (2021-2026)
  • Table 135. Middle East Gravid Treatment, by Application USD Million (2021-2026)
  • Table 136. Africa Gravid Treatment, by Type USD Million (2021-2026)
  • Table 137. Africa Gravid Treatment, by Application USD Million (2021-2026)
  • Table 138. North America Gravid Treatment, by Country USD Million (2021-2026)
  • Table 139. North America Gravid Treatment, by Type USD Million (2021-2026)
  • Table 140. North America Gravid Treatment, by Application USD Million (2021-2026)
  • Table 141. United States Gravid Treatment, by Type USD Million (2021-2026)
  • Table 142. United States Gravid Treatment, by Application USD Million (2021-2026)
  • Table 143. Canada Gravid Treatment, by Type USD Million (2021-2026)
  • Table 144. Canada Gravid Treatment, by Application USD Million (2021-2026)
  • Table 145. Mexico Gravid Treatment, by Type USD Million (2021-2026)
  • Table 146. Mexico Gravid Treatment, by Application USD Million (2021-2026)
  • Table 147. Research Programs/Design for This Report
  • Table 148. Key Data Information from Secondary Sources
  • Table 149. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gravid Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Gravid Treatment: by Application USD Million (2015-2020)
  • Figure 6. South America Gravid Treatment Share (%), by Country
  • Figure 7. Asia Pacific Gravid Treatment Share (%), by Country
  • Figure 8. Europe Gravid Treatment Share (%), by Country
  • Figure 9. MEA Gravid Treatment Share (%), by Country
  • Figure 10. North America Gravid Treatment Share (%), by Country
  • Figure 11. Global Gravid Treatment share by Players 2020 (%)
  • Figure 12. Global Gravid Treatment share by Players (Top 3) 2020(%)
  • Figure 13. Global Gravid Treatment share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Laboratoires Expanscience (France) Revenue, Net Income and Gross profit
  • Figure 16. Laboratoires Expanscience (France) Revenue: by Geography 2020
  • Figure 17. Clarins Group (France) Revenue, Net Income and Gross profit
  • Figure 18. Clarins Group (France) Revenue: by Geography 2020
  • Figure 19. Merz North AmericaInc. (Merz Group) (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Merz North AmericaInc. (Merz Group) (Germany) Revenue: by Geography 2020
  • Figure 21. E.T. Browne Drug (United States) Revenue, Net Income and Gross profit
  • Figure 22. E.T. Browne Drug (United States) Revenue: by Geography 2020
  • Figure 23. Syneron Medical Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Syneron Medical Ltd. (United States) Revenue: by Geography 2020
  • Figure 25. Union-Swiss (Pty) Ltd. (South Africa) Revenue, Net Income and Gross profit
  • Figure 26. Union-Swiss (Pty) Ltd. (South Africa) Revenue: by Geography 2020
  • Figure 27. Basq Skincare (United States) Revenue, Net Income and Gross profit
  • Figure 28. Basq Skincare (United States) Revenue: by Geography 2020
  • Figure 29. Ellipse A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 30. Ellipse A/S (Denmark) Revenue: by Geography 2020
  • Figure 31. The Boppy Company (United States) Revenue, Net Income and Gross profit
  • Figure 32. The Boppy Company (United States) Revenue: by Geography 2020
  • Figure 33. Helix BioMedix (United States) Revenue, Net Income and Gross profit
  • Figure 34. Helix BioMedix (United States) Revenue: by Geography 2020
  • Figure 35. Global Gravid Treatment: by Type USD Million (2021-2026)
  • Figure 36. Global Gravid Treatment: by Application USD Million (2021-2026)
  • Figure 37. South America Gravid Treatment Share (%), by Country
  • Figure 38. Asia Pacific Gravid Treatment Share (%), by Country
  • Figure 39. Europe Gravid Treatment Share (%), by Country
  • Figure 40. MEA Gravid Treatment Share (%), by Country
  • Figure 41. North America Gravid Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Laboratoires Expanscience (France)
  • Clarins Group (France)
  • Merz North AmericaInc. (Merz Group) (Germany)
  • E.T. Browne Drug (United States)
  • Syneron Medical Ltd. (United States)
  • Union-Swiss (Pty) Ltd. (South Africa)
  • Basq Skincare (United States)
  • Ellipse A/S (Denmark)
  • The Boppy Company (United States)
  • Helix BioMedix (United States)
Additional players considered in the study are as follows:
Weleda AG , Dermaclara , Mama Mio US , Centre Light Solutions
Select User Access Type

Key Highlights of Report


Jan 2021 250 Pages 56 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Gravid Treatment Quantitative research analysis
Gravid Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Rising Number of Gravid Treatment Clinics in Developing Countries " is seen as one of major growth factors of Gravid Treatment Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Gravid Treatment Report?

Have a Query? Click Here

Other Related Reports

Glaucoma Eye Drops Comprehensive Study by Type (Prostaglandin Analogs, Prostaglandin Analogs, Alpha Agonists, Carbonic Anhydrase Inhibitors (Cais), Rho Khinase Inhibitors, Combined Medications, Other...
$ 3650
Photosensitizer Drug Comprehensive Study by Type (Porphyrin Derivatives (PD) (Hematoporphyrin Derivative (HpD), Benzoporphyrin Derivative (BPD), Texaphyrins, Others), Aminolevulinic acid (ALA), Chlor...
$ 3750
Oral Antiseptics Comprehensive Study by Type (Chlorhexidine Gluconate, Essential Oils, Methyl Salicylate, Povidone-Iodine, Hydrogen Peroxide, Cetylpyridinium Chloride), Application (Dental Care, Oral...
$ 3650
Respiratory Drugs Comprehensive Study by Type (Antiasthmatic combinations, Antihistamines, Antitussives, Bronchodilators, Others), Disease Type (Asthma, COPD, Allergic rhinitis, Cystic fibrosis, Idio...
$ 3650
Pasireotide Comprehensive Study by Form (Liquid Solution, Powder), Dosage (0.3mg/ml, 0.6mg/ml, 0.9mg/ml), End User (Hospital, Pharmacy) Players and Region - Americas Market Outlook to 2026
$ 3500
Adenosine Deaminase Deficiency Drugs Comprehensive Study by Type (Adagen, Revcovi), Application (Hospitals, Clinic, Ambulatory Surgical Centers), Sales Channel (Prescription Drugs, Over-the-Counter D...
$ 3500